Understanding gun violence risk factors, along with effective policies and interventions, can help reverse the alarming rate of global gun violence—but researchers face multiple challenges in achieving these goals, according to a new commentary published in The Lancet. 

The small molecule could slow or stop the progression of Parkinson’s disease and related brain disorders, rather than just treating symptoms.

The drug candidate works by blocking and reversing the toxic build-up of protein believed to drive these diseases, preventing it from spreading through the brain.

The compound is one of the first to target multiple disease pathways at once, including the interaction between key proteins linked to faster cognitive decline.

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers from Mass General Brigham Cancer Institute evaluated the long-term efficacy and safety of the FDA-approved drug pralsetinib, which targets RET. Investigators found that treatment led to durable responses with manageable safety profiles in 281 patients with advanced or metastatic RET fusion-positive NSCLCs. Results are published in Journal of Clinical Oncology.